Amulet buys SynterActHCR from Gryphon

By Gareth Macdonald

- Last updated on GMT

Synteract too, PE firms back in the CRO habit: Amulet buys contractor from Gryphon
Synteract too, PE firms back in the CRO habit: Amulet buys contractor from Gryphon

Related tags Clinical trial

Amulet Capital Partners has bought SynteractHCR in its first acquisition in the contract research sector.

Private equity investment firm Amulet – which was founded last year – paid former SynterActHCR owner Gryphon Investors an undisclosed sum for the Phase I-IV focused clinical services firm.

SynteractHCR CEO Wendel Barr said funding from the CROs new owners will “allow us to enhance our full service capabilities, hire even more international clinical development experts to support global trials.​”

Gryphon bought Synteract in 2008. In 2013​, Gryphon bought Munich-based Harrison Clinical Research and merged it Synteract citing a desire to expand the firm’s presence in Europe and to move into the medical device contracting space as a major motivation.

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars